Targeting IL-5 in severe asthma: a DREAM come true?
- PMID: 22901871
- DOI: 10.1016/S0140-6736(12)61132-5
Targeting IL-5 in severe asthma: a DREAM come true?
Comment on
-
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.Lancet. 2012 Aug 18;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X. Lancet. 2012. PMID: 22901886 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical